Clinical trials: Neurological; Disorder, Nervous System
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071949
- Testing
- Adezunap
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Hearing Loss
Evaluation of Software for Self-Fitting of Hearing Aids by People With Hearing Loss
The purpose of the study is to evaluate the efficacy of a prototype app for the self-fitting of hearing aids.
- Trial name
- NCT05280808
- Testing
- Experimental phone app used for self-fitting of hearing aids
- Where
- Australia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Sonova AG
Geographic Atrophy, Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study, and not due to any safety…
- Trial name
- NCT01527500
- Testing
- LFG316, LFG316 Lower dose
- Where
- 19 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Dural Sealing
DuraSeal Exact Spine Sealant System Post-Approval Study
This is a non-randomized, post-approval study to further evaluate the rate of post-operative Cerebral Spinal Fluid (CSF) leaks in subjects who undergo a spinal procedure and receive DuraSeal Exact Spine Sealant System.
- Trial name
- DuraSeal PAS (NCT01410864)
- Testing
- DuraSeal Exact Spine Sealant System, Control
- Where
- 36 sites in United States
- Volunteers
- 924 people
- Sponsor
- Integra LifeSciences Corporation
Migraine Without Aura
Migraine STImulation Crisis of Migraine
Migraine is a neurovascular disease whose prevalence is estimated at almost 20% of the adult population. Currently, there is no treatment for migraine.
- Trial name
- MISTIC (NCT04568252)
- Testing
- Wristband with millimeter wave emission.
- Where
- 6 sites in France
- Volunteers
- 140 people
- Sponsor
- Remedee SA
Hearing Loss, Sensorineural
Design Improvements With SONNET 3
Measuring user-reported satisfaction with the latest behind-the-ear (BTE) audio processor model.
- Trial name
- NCT06597747
- Testing
- Audio processor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Med-El Corporation
Tinnitus, Hyperacusis
Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis
Neuromonics TInnitus Treatment CALM study is a multi site study of 100 adult subjects with clinically significant disturbing tinnitus to evaluate outcome measures using the FDA cleared Neuromonics treatment after 6, 12, 24 and 36…
- Trial name
- CALM (NCT00730834)
- Testing
- Oasis
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Neuromonics, Inc.
Hyperphagia, Prader-Willi Syndrome
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us about the safety of ARD-101.
- Conditions
- Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome
- Trial name
- NCT07197034
- Testing
- ARD-101
- Where
- 30 sites in United States, Australia and 3 more
- Volunteers
- 19 people
- Sponsor
- Aardvark Therapeutics, Inc.
Prader-Willi Syndrome
A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome
This was a study investigating RAD011 in participants diagnosed with Prader-Willi Syndrome (PWS). The primary objective of the Phase 2 part of this study was to assess the safety and tolerability of multiple dose levels of RAD011…
- Trial name
- NCT05098509
- Testing
- RAD011
- Where
- 8 sites in United States
- Volunteers
- 4 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Fragile X Syndrome
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery).
- Trial name
- NCT03802799
- Testing
- ZYN002 - Cannabidiol Transdermal Gel
- Where
- 26 sites in United States, Australia and 2 more
- Volunteers
- 476 people
- Sponsor
- Zynerba Pharmaceuticals, Inc.
Sarcopenia
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in patients with sarcopenia.
- Trial name
- NCT01963598
- Testing
- REGN1033 (SAR391786)
- Where
- 43 sites in United States, France and 2 more
- Volunteers
- 253 people
- Sponsor
- Regeneron Pharmaceuticals
Agitation, Dementia
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 28 doses within a 12-week treatment period.
- Trial name
- NCT05271552
- Testing
- BXCL501
- Where
- 11 sites in United States
- Volunteers
- 151 people
- Sponsor
- BioXcel Therapeutics Inc
Neuropathic Pain
Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain
The trial is designed to evaluate the efficacy and tolerability of carbamazepine in neuropathic pain in diabetic patients
- Trial name
- NCT01089855
- Testing
- Carbamazepine
- Where
- Morocco
- Volunteers
- 123 people
- Sponsor
- Novartis
Pain, Post Operative Pain
Phase II Study of Inhaled AeroLEF for Analgesia After ACL Knee Surgery
To evaluate the safety and efficacy of self-titration to effective analgesia with inhaled AeroLEF in patients with moderate/severe acute pain in the post-surgical setting.
- Trial name
- Pain (NCT00791804)
- Testing
- AeroLEF
- Where
- 2 sites in Canada
- Volunteers
- 19 people
- Sponsor
- YM BioSciences
Attention Deficit Hyperactivity Disorder (ADHD)
Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children
This study aims to evaluate the efficacy of an Omega-3 Fatty Acid Supplement on improving the Attention Deficit Hyperactivity Disorder (ADHD) clinical symptoms.
- Trial name
- ECOMEGA (NCT02248948)
- Testing
- Omega-3 Fatty Acids, Medium Chain Triglycerides
- Where
- Spain
- Volunteers
- 231 people
- Sponsor
- Laboratorios Ordesa
Huntington's Disease, Chorea
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea
This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.
- Trial name
- NCT01019473
- Testing
- AFQ056
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Post-Amputation Pain, Phantom Limb Pain
Electrical Stimulation for the Treatment of Post-Amputation Pain Using the SPRINT System
The purpose of this study is to determine if electrical stimulation (small levels of electricity) can safely and effectively reduce post-amputation pain. This study involves a device called the SPRINT System.
- Conditions
- Post-Amputation Pain, Phantom Limb Pain, Residual Limb Pain
- Trial name
- NCT01996254
- Testing
- SPRINT Peripheral Nerve Stimulation (PNS) System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- SPR Therapeutics, Inc.
Parkinson Disease, Dyskinesia, Medication-Induced
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia
The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia.
- Trial name
- NCT05297201
- Testing
- CPL500036 - low dose, CPL500036 - high dose
- Where
- 16 sites in Poland, Ukraine
- Volunteers
- 105 people
- Sponsor
- Celon Pharma SA
Hearing Loss, Hearing Impairment
Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
The objective of this pilot study is to explore whether repeat doses of AUT00063 can provide an indication of improvement in performance of tests across a battery of speech and hearing assessments in cochlear implant users.
- Trial name
- NCT02832128
- Testing
- AUT00063
- Where
- 4 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Autifony Therapeutics Limited
Bipolar Disorder, Schizophrenia
Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)
This study will assess asenapine (Sycrest®) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL®CONSTA®) and olanzapine (Zyprexa®).
- Trial name
- NCT01495741
- Volunteers
- 42 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.